Should You Buy Rocket Pharmaceuticals Inc (RCKT) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/30
RCKT is not a good buy right now. The stock is in a clear downtrend (bearish moving averages and weakening MACD), sentiment is pressured by recent analyst downgrades/price-target cuts and stated program risk (Danon), and options flow is skewed bearish on volume. For an impatient investor who doesn’t want to wait for an optimal entry, this setup does not justify buying at current levels.
Technical Analysis
Price/Trend: Strong bearish trend with SMA_200 > SMA_20 > SMA_5, indicating persistent downside momentum across short-, medium-, and long-term timeframes.
Momentum: MACD histogram at -0.0434 is below zero and negatively expanding, suggesting downside momentum is still building rather than stabilizing.
RSI: RSI_6 at ~25 is oversold, which can support a short-lived bounce, but oversold readings can persist in strong downtrends—so it’s not a reliable buy trigger here.
Levels: Pivot 3.645 (overhead), resistance at R1 3.878 then R2 4.022. Support is near S1 3.413 (already being tested/nearby) and S2 3.269. A breakdown toward/through 3.269 would reinforce the bearish trend.
Pattern-based drift: Similar-pattern stats imply slightly negative near-term bias (about -3.15% over the next week) with only mild positive skew over the next month (+0.99%), consistent with “bearish now, maybe mean-revert later.”
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.